阿洛斯特里:好的,坏的和丑的
1Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina kenakin@email.unc.edu.
The Journal of pharmacology and experimental therapeutics
|November 2, 2023
概括
具有独特的结合性和构造性质的菌分子正在成为有前途的治疗剂. 了解它们的功能和发现技术对于开发新药至关重要.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 药物发现 药物发现 药物发现
背景情况:
- 艾洛斯特分子越来越多地被认为是潜在的治疗剂.
- 功能性查正在推动新型全性化合物的发现.
- 类蛋白质具有不同的结合点和形状变化机制.
研究的目的:
- 审查所有菌分子作为药物候选物的意义.
- 为了解释全性蛋白质的独特特性.
- 概述了优化全分子发现的技术.
主要方法:
- 关于全调节的当前文献的综述.
- 功能查方法的分析.
- 检查G蛋白结合受体 (GPCR) 的全性机制.
主要成果:
- 基调节剂提供独特的药理学益处,特别是对于GPCRs.
- 杂货发现活动需要专门的考虑才能取得成功.
- 对于科学家在药物开发方面来说,了解质功能是必不可少的.
结论:
- 菌分子代表了一类有价值的潜在治疗药物.
- 专门的技术是必要的,以表征和优化全性药物发现.
- 对全性机制的进一步研究将推动药物化学的创新.
相关概念视频
Allosteric Regulation
58.0K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
58.0K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Cooperative Allosteric Transitions
7.9K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.9K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Cholinergic Antagonists: Pharmacological Actions
1.1K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
698
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
698


